Ultrasonic System for Cataract Characterization and Optimal Phacoemulsification Energy Evaluation

Cataract Clinical Trial

— CATARCTUS  

Official title:

Development of a Medical Device Based on Ultrasounds for Objective Cataract Characterization and Optimal Phacoemulsification Energy Evaluation

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT04461912
• Other study ID #: POCI-01-0145-FEDER-028758
• Status: Not yet recruiting
• Phase: N/A
• Start date: June 1, 2021
• Est. completion date: September 1, 2022

Study information

• Verified date: April 2021
• Source: University of Coimbra
• Contact: Jaime Santos, PhD
• Phone: +351 239 796 200
• Email: jaime[@]deec.uc.pt
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study aims to assess the performance of an ultrasonic system for automatic classification of cataract type and severity, as well as the estimation of the optimal phacoemulsification energy. Ultrasonic signals from the lens will be acquired with the Experimental Medical Device (ESUS) in participants with cataract, and in healthy subjects (control).

The proposed technique may represent an important advance in cataract treatment. The quantitative and automatic classification of cataract type and severity, and the estimation of the optimal phacoemulsification energy is may represent a valuable tool for surgical planning, reducing complications associated to excessive levels of phacoemulsification energy, as well as the times spent on surgeries. This device may be relevant not only for patients, but also for public health systems, reducing waiting lists and associated costs.

Description:

This is a prospective, pivotal, non-blinded study. Fifty (50) participants will be recruited at the Coimbra Surgical Center of Portugal. The study will be conducted on subjects with age-related cataract, and on healthy subjects as control group. Since this is a pilot study, no sample size estimation has been implemented. The statistical power will be determined at the end of the study. Only per-protocol participants will be considered on statistical analysis.

Procedures involved. The ultrasonic system (Experimental Medical Device - ESUS) works in A-scan mode, with an acoustic working frequency of 20 MHz. From the ultrasonic signals backscattered from the lenses, acoustic parameters will be extracted, and used for automatic algorithms implementation. This study will be implemented once.

Slit lamp with LOCS III classification will be used as comparator. Contrast sensitivity test results will be used for incipient cataract detection, where slit lamp may present some limitations. Optical coherence tomography and specular microscopy will help on detecting postoperative complications; other complications identified by the physician will be also considered. Surgical parameters as phacoemulsification energy and surgical time will help on phacoemulsification energy evaluation.

Safety assessment. The system uses an ophthalmic probe. There are not anticipated adverse events related to the procedures involved in the use of the ultrasonic system, or any other procedure in the protocol. The safety conditions will be monitored through the occurrence of unanticipated adverse events or serious adverse events. If these situations occur, the event will be reported to the competent authorities (in agreement with the current regulation) and the corrective actions will be implemented.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 50
• Est. completion date: September 1, 2022
• Est. primary completion date: March 1, 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 50 Years to 70 Years

Eligibility

Inclusion criteria:

Cataract group:

• Patients with age-related cataract;

• Indication of phacoemulsification surgery

Control group:

• Patients without cataract

Exclusion criteria:

• Presence of any other ophthalmological condition or systemic disease that could affect the results

Related Conditions & MeSH terms

• Cataract
• Ultrasound Therapy; Complications

Intervention

Device:
• Eye Scan Ultrasound System (ESUS)
• For the ultrasonic signals acquisitions, an ophthalmic probe working in A-mode scan, must be coupled to the cornea. To reduce the discomfort generated by coupling the probe, topical anaesthesia (oxybuprocaine hydrochloride) will be applied before starting acquisitions. However, if the participant has some known contraindication to this anaesthetic, in replacement, a disposable neutral contact lens will be used as coupling medium between the probe and the cornea. The acquisitions are initiated through a starting button in the system's user interface, and the probe must be kept by few seconds for automatic signals records. During this period, signals are visualized in the user interface. Finally the probe is uncoupled, and the acquired signals are saved.

Locations

Country	Name	City	State
Portugal	Centro Cirúrgico de Coimbra (CCCI)	Coimbra

Sponsors (2)

Lead Sponsor	Collaborator
University of Coimbra	Fundação para a Ciência e a Tecnologia

Country where clinical trial is conducted

Portugal, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Presence of Cataract	Presence of cataract obtained with the Experimental Medical Device (ESUS)	baseline
Secondary	Cataract classification	Cataract type and severity obtained with the Experimental Medical Device (ESUS) - based on the LOCS III (Lens Opacity Classification System)	baseline
Secondary	Cataract hardness	Cataract hardness estimated with the Experimental Medical Device (in Gpa)	before the intervention/procedure/surgery
Secondary	Phacoemulsification energy	Phacoemulsification energy level estimated with the Experimental Medical Device in the participants performing cataract surgery (considering the phacoemulsification energy parameters provided by the phacoemulsifier).	immediately after the intervention/procedure/surgery